Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with preferential affinity for the GABA-A receptor alpha-2 subunit. Unlike traditional 1,4-benzodiazepines, it exhibits a broader therapeutic index and reduced sedative profile, though tolerance to antiseizure effects frequently develops over time.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
* Off-label: Treatment of refractory epilepsy, focal seizures, and status epilepticus (refractory).
## Adult Dosing
* **Initial:** 5 mg twice daily for 7 days.
* **Maintenance:** Increase to a total of 20 mg daily (10 mg twice daily) by the end of week 2.
* **Maximum:** 40 mg daily (administered in two divided doses).
* *Note: Doses >20 mg/day should be divided into twice-daily administration.*
## Pediatric Dosing (≥2 years)
* **Weight-based dosing:**
* **≤ 30 kg:** 5 mg once daily; may increase to 10 mg twice daily after 1 week.
* **> 30 kg:** 5 mg twice daily; may increase to 20 mg daily (10 mg twice daily) after 1 week.
* **Maximum:** 40 mg daily.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose by 50% and titrate slowly. Avoid in severe impairment (Child-Pugh Class C).
* **Renal Impairment:** Monitor closely; dosage adjustments are not systematically defined, but use caution due to potential accumulation of active metabolites (N-desmethylclobazam).
* **CYP2C19 Poor Metabolizers:** Start at 50% of the recommended dose and titrate cautiously, as N-desmethylclobazam levels may be 2–5 times higher.
## Contraindications
* Known hypersensitivity to clobazam.
* History of severe respiratory depression.
## Adverse Effects
* **Common:** Somnolence, sedation, fever, lethargy, drooling (sialorrhea), constipation, ataxia, and upper respiratory tract infections.
* **Serious:** Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, suicidal ideation/behavior, and withdrawal seizures upon abrupt cessation.
## Key Drug Interactions
* **CYP2C19 inhibitors (e.g., fluconazole, fluvoxamine):** Significantly increase levels of N-desmethylclobazam (active metabolite).
* **CYP2C19 inducers (e.g., rifampin, St. John's wort):** Reduce efficacy.
* **CNS Depressants:** Enhances sedation (alcohol, opioids, antihistamines).
* **Stiripentol:** Increases clobazam plasma levels significantly; often requires a 50% reduction in clobazam dose to avoid toxicity.
* **Hormonal Contraceptives:** May reduce efficacy; use barrier methods.
## Monitoring
* **Efficacy:** Seizure frequency and duration.
* **Safety:** Monitor for CNS depression and respiratory stability.
* **Skin:** Observe for signs of rash (e.g., blistering, mucosal involvement) and discontinue immediately if suspected SJS/TEN.
* **Mental Health:** Monitor for new or worsening depression or suicidal ideation.
## Clinical Pearls
* **Withdrawal Hazard:** Abrupt discontinuation can precipitate status epilepticus; always taper gradually over several weeks.
* **Substitutability:** Oral suspension and tablets are bioequivalent; ensure the calibrated measuring device is used for suspension.
* **Tolerance:** The therapeutic effect may diminish over time due to the development of anticonvulsant tolerance.
* **Sialorrhea:** Drooling is a common dose-limiting side effect in pediatric patients; consider antimuscarinics if medically necessary.
***
**Educational Disclaimer:** This information is for educational purposes for healthcare professionals. Clinical practice guidelines and local protocols vary. Always verify current prescribing information, contraindications, and drug interactions using official labeling (FDA/EMA) or institutional clinical decision support tools before prescribing.
